Repository logo
  • English
  • Français
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
  • Communities & Collections
  • Research Outputs
  • Fundings & Projects
  • People
  • Statistics
  • English
  • Français
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Centre for Leadership in Global Health
  3. Dr. Ernest Tambo
  4. Sustainable Pharmaceutical Manufacturing and Supply Chain Diversification for Economic Growth in Africa: Barriers, Opportunities, and Policy Pathways
 
  • Details
Options

Sustainable Pharmaceutical Manufacturing and Supply Chain Diversification for Economic Growth in Africa: Barriers, Opportunities, and Policy Pathways

Journal
Biotechnology Journal International
ISSN
2456-7051
Date Issued
2026-01-21
Author(s)
Ernest Tambo
DOI
https://doi.org/10.9734/bji/2026/v30i1824
Abstract
While Africa continent has high potential due to its large and youthful population, manufacturing remains underdeveloped, with only 2% of global manufactured goods originating from Africa. Inadequate and unreliable infrastructure is one of the most critical barriers to manufacturing implementation and broad growth. Little is documented on biomanufacturing readiness and supply chain systems performance and robustness that are essential for safe and efficacious vaccines, medicine and other diagnostic products. This review article highlights biopharmaceutical manufacturing and supply chain management regulatory ecosystem and engagement, workforce and infrastructure capacities implementation strategies. Findings showed that pharmaceutical manufacturing in Africa is a rapidly growing, strategic focus for health sovereignty, aiming to shift from importing over 99% of its vaccines to producing 60% locally by 2040 through massive workforce development, strategic partnerships, and targeted investments. This review article highlights the biomanufacturing regulatory ecosystem and policies implementation to targeted capacity building strategies in enhancing sustainable production and supply chain systems resilience, efficiency and access and uptake effectiveness for economic growth and well-being, Addressing implementation barriers and knowledge gaps is crucial in harnessing and fast-tracking vaccines and medical products scale production and wide availability against preventable infectious diseases and non-communicable diseases among under-served and vulnerable populations across Africa and global south. Findings revealed that key barriers and challenges include a shortage of skilled labor, complex and inconsistent regulatory environments, inadequate and unreliable infrastructure like geopolitics power increasing operational costs and limits production, fragmented markets, transportation, inefficient roads and ports, which drives up freight costs and causes significant supply chain management bottlenecks, and limited allocation domestic finance. Key strategies in national and regional diversification of manufacturing are highlighted to significantly impact socio-economic growth by fostering innovation, creating jobs, and enabling sustainable production of various goods. Advancing biomanufacturing basic and advanced research to industrial-scale production and sustainability approaches. Africa’s development and transformation relies on biomanufacturing actionable outcomes which is crucial for a thriving bioeconomy immense opportunities driven by the Africa Union Platform for Harmonized African Health products Manufacturing (PHAHM) to build capacity for vaccines, diagnostics, and therapeutics. This calls for the urgent need for integration and sustainability drivers and evidence-based biomanufacturing policies and regulations, productivity and economic development strategies. Fostering public-private biomanufacturing partnerships and co-investment actions plans. Boosting integrative vaccines biomanufacturing national regulatory and ethics engagement, licensure pathways and hamonized reliance approaches through advancing data sharing and standard practice for programmatic vaccine biomanufacturing decision-making and resilience across borders. Data-driven and evidence-informed decisions safe and effective biomedical products development, scale production, availability,low-cost and uptake compliance have shown signifficant global and public health benefits and returns impact. Biopharmaceutical manufacturing and biotechnologies skilled workforce development and programmatic plans including risk mitigation and supply chain capabilities across Africa have potential social and pubic health impact and driving “the Africa w Want”, while addressing manufacturing regulatory processes and high cost investment and global supply chain complexities and vulnerabilities issues and gaps is core across Africa and worldwide.
File(s)
No Thumbnail Available
Name

Tambo3012025BJI148194.pdf

Size

374.1 KB

Format

Adobe PDF

Checksum

(MD5):b8656a3133ec63aa29d552e833817724

  • logo.footer.image.logo
  • grid-colum.footer.image.logo
Rwanda:

Office Hours: 8:00 a.m. - 5:00 p.m.
p: 0786.405.072
Kigali Heights, Plot 772
KG 7 Ave., 5th Floor
PO Box 6955
Kigali

United States:

Office Hours: 9:00 a.m. - 5:00 p.m.
800 Boylston Street, Suite 300
Boston, MA 02199

Connect with us:

View our privacy policy.

If you are interested in working for the university, please visit our job board for open positions.

To get in touch with UGHE, please send us an email.

Copyright © 2024, UGHE.org All Rights Reserved

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback